PIM2
Serine/threonine-protein kinase pim-2
As of the edition of 20 October 2026, PIM2 (serine/threonine-protein kinase pim-2, UniProt Q9P1W9) has 3 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9P1W9
- How well studied
- Chemical tools exist; no approved drug acts on it
- Solved structures
- 2
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Urinary and reproductive
- Registered trials of its drugs
- 8
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| LGH-447 | Went quiet | Phase 1 | none listed |
| SGI-1776 | Stopped | Phase 1 | none listed |
| AZD-1208 | Stopped | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Novartis | Route A |
| Otsuka | Route A |
The other 0 companies at PIM2
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at PIM2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.